People are watching the Life Sciences industry like never before. What do we see for companies preparing for 2022? Three trends will likely shape everything – from operating models to customer engagement – in the near future.
The rise of Internet of Medical Things (IoMT).
This is IoT technology combined with MedTech tools aimed at modernizing medical care. Investment in this area will dominate smart manufacturing. Life Sciences plants and supply chains will transform with the help of intelligent automation, AR/VR-assisted training on the shop floor and the dramatic improvements that can happen to processes through process mining and automation. The industry will continue to expand and find practical applications for IoMT as a way to collect, manage, process and store medical data.
A new focus on efficiency and speed in the R&D process.
The industry ramped up R&D to develop a COVID-19 vaccine in record time and will take advantage of the momentum in 2022. Companies will use decentralized trials, genomics and automation to increase efficiency. AI-assisted research will play a larger role in identifying molecules, predicting efficiency/toxicity and enhancing development processes to streamline clinical trials and boost early detection capabilities.
Greater collaboration across large bio-pharma companies, startups and academia.
Larger companies will increasingly rely on academia and small, tech-focused and research-oriented organizations to bring technology advantage, expand pipeline candidates, accelerate trials or simply find lucrative area to invest. Companies across the Life Sciences industry will spend 2022 applying the lessons they learned during the pandemic to push the industry forward.
Contact us to learn more.
About the authors
Jennifer Stein
